
Biochemical Pharmacology p. 329 - 338 (2003)
Update date:2022-07-30
Topics:
Harper, Jacquie L.
Camerini-Otero, Carol S.
Li, An-Hu
Kim, Soon-Ai
Jacobson, Kenneth A.
Daly, John W.
A series of 1,4-dihydropyridines (DHPs) were investigated as inhibitors of capacitative calcium influx through store-operated calcium (SOC) channels. Such channels activate after ATP-elicited release of inositol trisphosphate (IP3)-sensitive calcium stores in leukemia HL-60 cells. The most potent DHPs were those containing a 4-phenyl group with an electron-withdrawing substituent, such as m- or p-nitro- or m-trifluoromethyl (IC50 values: 3-6μM). Benzyl esters, corresponding to the usual ethyl/methyl esters of the DHPs developed as L-type calcium channel blockers, retained potency at SOC channels, as did N-substituted DHPs. N-Methylation reduced by orders of magnitude the potency at L-type channels resulting in DHPs nearly equipotent at SOC and L-type channels. DHPs with N-ethyl, N-allyl, and N-propargyl groups also had similar potencies at SOC and L-type channels. Replacement of the usual 6-methyl group of DHPs with larger groups, such as cyclobutyl or phenyl, eliminated activity at the SOC channels; such DHPs instead elicited formation of inositol phosphates and release of IP3-sensitive calcium stores. Other DHPs also caused a release of calcium stores, but usually at significantly higher concentrations than those required for the inhibition of capacitative calcium influx. Certain DHPs appeared to cause an incomplete blockade of SOC channel-dependent elevations of calcium, suggesting the presence of more than one class of such channels in HL-60 cells. N-Methylnitrendipine (IC50 2.6μM, MRS 1844) and N-propargylnifrendipine (IC50 1.7μM, MRS 1845) represent possible lead compounds for the development of selective SOC channel inhibitors.
View MoreNanjing Zelang Medical Technology Co. Ltd
Contact:86-25-83063290/13770714480
Address:Ganjiabian 108# 01 Unit,701-702 room,Yao Hua Street,Qixia District,Nanjing,Jiangsu,China
Hangzhou Eastbiopharm Co.,Ltd.
Contact:+86-571-88931780
Address:Hangzhou,China
Shanghai better-in Medical Technology Co.,LTD.
Contact:+86-21-38921049
Address:Lane 720 zhangjianggaoke cailun road, Pudong, Shanghai, room 513
BrightGene Bio-Medical Technology Co., Ltd.
website:https://en.bright-gene.com/
Contact:+86-512-62551801
Address:Building C25 - C31, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
MS( MAOSHENG )Chemical CO.,LTD
Contact:+86-519-82726678.82726378
Address:TAOXI INDUSTRY ZONE JINTAN
Doi:10.1021/ja0358044
(2003)Doi:10.1021/ja01153a504
(1951)Doi:10.1007/BF02234855
(1999)Doi:10.1002/anie.201504072
(2015)Doi:10.1016/S0020-1693(00)91707-9
(1976)Doi:10.1016/j.jfluchem.2017.07.006
(2017)